Prognosis factors of predicting survival in spontaneously ruptured hepatocellular carcinoma

Hepatol Int. 2022 Dec;16(6):1330-1338. doi: 10.1007/s12072-022-10403-x. Epub 2022 Aug 25.

Abstract

Aim: To investigate predictors affecting survival in patients with spontaneously ruptured hepatocellular carcinoma (srHCC).

Methods: One-hundred-and-twenty-seven patients experiencing srHCC between January 2010 and December 2020 were enrolled. The clinical features, treatments, and outcomes were reviewed. Statistics included univariate analysis, Kaplan-Meier analysis, multivariate analysis using Cox proportional hazards model and logistic regression model, and receiver operating characteristic (ROC) curve analysis.

Results: Of the 127 srHCC patients, 24, 42, and 61 patients received conservative treatment, surgical treatment, and transarterial chemoembolization/embolization (TACE/TAE) treatment at HCC rupture, respectively. The largest tumor size [hazard ratio (HR) 1.127; p < 0.001], Barcelona-Clinic Liver Cancer (BCLC) stage (HR 2.184, p = 0.023), international normalized ratio (INR; HR 3.895; p = 0.012), total bilirubin level (TBil; HR 1.014; p = 0.014), TACE after rupture (compared with conservative treatment) (HR 0.549; p = 0.029), TACE/TAE and surgery at rupture, and albumin level (HR 0.949; p = 0.017) were independent predictors affecting overall survival. A survival predictive model for HCC rupture (SPHR) using these predictors was created. ROC analysis showed that the area under the curve (AUC) of the SPHR model for 30 day survival was 0.925, and the AUCs of the model for end-stage liver disease (MELD) score and Child-Pugh score for 30 day survival were 0.767 and 0.757, respectively.

Conclusion: The largest tumor size, advanced BCLC stage, higher INR and TBil, lower albumin, and conservative treatment were negative independent predictors for overall survival. The SPHR model may be more suitable than the MELD score and Child-Pugh score for predicting 30 day survival in srHCC.

Keywords: Child–Pugh; Hepatocellular carcinoma; MELD; Predictive model; Prognosis; Risk factors; Rupture; Surgical treatment; Survival; Transarterial embolization.

MeSH terms

  • Albumins
  • Carcinoma, Hepatocellular* / pathology
  • Chemoembolization, Therapeutic*
  • End Stage Liver Disease* / pathology
  • Humans
  • Liver Neoplasms* / pathology
  • Neoplasm Staging
  • Prognosis
  • Retrospective Studies
  • Severity of Illness Index
  • Treatment Outcome

Substances

  • Albumins